Ankylosing spondylitis
Drug research and approvals for ankylosing spondylitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 50 studies of ankylosing spondylitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 50
- Trials authorized in Canada: 13
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 50 recruiting on ClinicalTrials.gov ↗- Phase Ia Study of MST-931 in Healthy Adult SubjectsNCT07903493 · Phase 1 · Mabsoft Therapeutics (Shanghai) Co., Ltd. · starts Nov 30, 2026
- Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · Not reported · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · starts Nov 9, 2026
- Surface Topography and Radiographic Spinal Damage in Radiographic Axial SpondyloarthritisNCT07855393 · Not reported · Ankara Etlik City Hospital · starts Sep 19, 2026
- Efficacy of the Erector Spinae Plane Block for Persistent Back Pain in Patients With Ankylosing SpondylitisNCT07633730 · Not applicable · Marmara University · starts Jun 2, 2026
- Exploratory Investigation of the Acceptance and Utility of 14-day Trial Periods and Application-related Outcome…NCT07561255 · Not applicable · Wuerzburg University Hospital · starts Apr 10, 2026
- An Investigation of the Effect of Smartphone Usage Levels on Cervical Posture, Tongue Pressure, Balance, and Neck…NCT07627542 · Not reported · Merve Şahin · starts Apr 9, 2026
- Deep Breathing Combined With Core Stability Exercises in the Treatment of Patients With Ankylosing SpondylitisNCT07262294 · Not applicable · Beni-Suef University · starts Feb 1, 2026
- Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing…NCT07556224 · Not reported · China-Japan Friendship Hospital · starts Jan 19, 2026
- A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous…NCT07920861 · Phase 1 · Huabo Biopharm Co., Ltd. · starts Jan 19, 2026
- Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing…NCT07509775 · Not reported · China-Japan Friendship Hospital · starts Jan 19, 2026
Trials Authorized in Canada
The 10 newest of 13; search them all in Canada trials| Aug 13, 2025 | A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with radiographic axial…TULISOKIBART (MK-7240) | Merck & Co. (MSD) | Ongoing |
| Sep 3, 2021 | A phase 2 multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy and safety of cc-99677 in subjects with…BMS-986371 (CC-99677) | Bristol-Myers Squibb | Closed |
| Aug 31, 2020 | A phase 3, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of filgotinib in subjects with active ankylosing spondylitis…FILGOTINIB | Gilead Sciences | Closed |
| Aug 31, 2020 | A phase 3, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of filgotinib in subjects with active ankylosing spondylitis…FILGOTINIB | Gilead Sciences | Closed |
| Apr 23, 2018 | A phase 3, randomized, double-blind, placebo-controlled, study of the efficacy and safety of tofacitinib in subjects with active ankylosing spondylitis (as)TOFACITINIB (CP-690,550) | Pfizer | Closed |
| Nov 14, 2017 | A multicenter, open-label, extension study to evaluate the long term safety and efficacy of bimekizumab in subjects with ankylosing spondylitisBIMEKIZUMAB | UCB | Ongoing |
| Nov 10, 2017 | A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus gp2017…COSENTYX / GP2017 (ADALIMUMAB) | Novartis Pharmaceuticals Corporation | Closed |
| Aug 14, 2017 | A multicenter, randomized, double-blind, placebo controlled study evaluating the safety and efficacy of upadacitinib in subjects with active ankylosing…UPADACITINIB (ABT-494) | AbbVie | Closed |
| Nov 23, 2016 | A multicenter, phase 2b, randomized, double blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of bimekizumab in…BIMEKIZUMAB | UCB | Ongoing |
| Feb 13, 2015 | A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading…SECUKINUMAB (AIN457) | Novartis Pharmaceuticals Corporation | Ongoing |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 18, 2018 | Zesslyinfliximab · biosimilar | Sandoz GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA